VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder
Stock Information for Vistagen Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.